Opioid REMS Update

This presentation provides participants with information related to the Food and Drug Administration’s (FDA) requirement for a shared Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioid medications. A brief background of REMS will be presented, detailing the chronology, rationale, and steps taken. An update of the status of REMS will be detailed, along with a review of the educational blueprint for REMS education proposed by the FDA.

Related Content